Delving into the Latest Updates on KUR-111 with Synapse

Overview

Basic Info

Drug Type

Fusion protein

Synonyms

Target

PTH1R

Mechanism

PTH1R agonists(Parathyroid hormone receptor agonists), Osteogenesis stimulants

Therapeutic Areas

Other Diseases

Active Indication-

Inactive Indication

Fractures, Bone

Originator Organization

Kuros Biosciences Ltd.

Active Organization-

Inactive Organization

Kuros Biosurgery AG

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

For certain tibial plateau fractures the bone is compressed due to the force acting on the tibia during the accident. The void provoked by the compression of the bone is filled with an appropriate filling material and the fracture is fixated. I 0401 is a new bone graft substitute that has shown capacities to promote bone-healing. This study will test the safety and efficacy of I 0401 in the treatment of patients with tibial plateau fractures requiring grafting.

Start Date01 Nov 2006

Sponsor / Collaborator

Kuros Biosurgery AG

100 Clinical Results associated with KUR-111

Login to view more data

100 Translational Medicine associated with KUR-111

Login to view more data

100 Patents (Medical) associated with KUR-111

Login to view more data

100 Deals associated with KUR-111

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fractures, Bone	Phase 2	IT	Kuros Biosurgery AG	01 Nov 2006
Fractures, Bone	Phase 2	GB	Kuros Biosurgery AG	01 Nov 2006
Fractures, Bone	Phase 2	ES	Kuros Biosurgery AG	01 Nov 2006
Fractures, Bone	Phase 2	DE	Kuros Biosurgery AG	01 Nov 2006
Fractures, Bone	Phase 2	HU	Kuros Biosurgery AG	01 Nov 2006
Fractures, Bone	Phase 2	AU	Kuros Biosurgery AG	01 Nov 2006
Fractures, Bone	Phase 2	CH	Kuros Biosurgery AG	01 Nov 2006
Fractures, Bone	Phase 2	FR	Kuros Biosurgery AG	01 Nov 2006
Fractures, Bone	Phase 1	PL	Kuros Biosurgery AG	01 Nov 2006